Analysts expect C4 Therapeutics to report Q2 2026 revenue of $8.20 million and a loss of $0.23 per share, with the current stock price of $3.62 trading significantly below the $11.00 analyst target.
Investors are primarily focused on the clinical progress of cemsidomide, specifically the enrollment status for the Phase 2 MOMENTUM trial in multiple myeloma.
Recent developments include a newly initiated Phase 1b combination trial with elranatamab and an expanded strategic partnership with Roche for degrader-antibody conjugates. The company maintains a strong balance sheet with a cash runway extending into late 2028, providing stability as it advances its targeted protein degradation pipeline.